Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | Detection of circulating TTR aggregates: a potential novel biomarker for ATTR amyloidosis

Lorena Saelices Gomez • 27 May 2024
ISA 2024
Amyloidosis Rare Diseases

Lorena Saelices Gomez, PhD, UT Southwestern Medical Center, Dallas, TX, discusses her work in which transythretin (TTR) aggregates were detected in the blood of patients with ATTR amyloidosis using a peptide probe, which could potentially serve as a novel biomarker in this disease setting. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria for scientific consulting for Intellia and Attralus
Member of the advisory board of Alexion

More from Lorena Saelices Gomez

Knowledge gaps in our understanding of the pathophysiology of ATTR amyloidosis
2:38
Knowledge gaps in our understanding of the pathophysiology of ATTR amyloidosis
Lorena Saelices Gomez • 27 May 2024
Challenges in understanding and diagnosing ATTR amyloidosis
1:08
Challenges in understanding and diagnosing ATTR amyloidosis
Lorena Saelices Gomez • 27 May 2024
Sensitive detection of TTR aggregates for early diagnosis and monitoring of ATTR amyloidosis
3:05
Sensitive detection of TTR aggregates for early diagnosis and monitoring of ATTR amyloidosis
Lorena Saelices Gomez • 7 Sep 2022

Related Videos

Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
1:40
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
Naveen Pemmaraju • 30 May 2026
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
2:20
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
Naveen Pemmaraju • 29 May 2026
The importance of alloSCT in improving outcomes for patients with BPDCN
1:40
The importance of alloSCT in improving outcomes for patients with BPDCN
Naveen Pemmaraju • 29 May 2026
First results of LINKER-AL2: linvoseltamab in patients with R/R systemic AL amyloidosis
2:51
First results of LINKER-AL2: linvoseltamab in patients with R/R systemic AL amyloidosis
Hans Lee • 30 May 2026
The content of VJHemOnc is intended for healthcare professionals